Bank of Montreal Can Has $11.14 Million Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Bank of Montreal Can raised its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 1.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 69,973 shares of the company’s stock after purchasing an additional 809 shares during the quarter. Bank of Montreal Can’s holdings in TransMedics Group were worth $11,136,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TMDX. Vaughan Nelson Investment Management L.P. acquired a new position in shares of TransMedics Group in the second quarter worth $39,862,000. Driehaus Capital Management LLC grew its stake in TransMedics Group by 15.8% in the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after purchasing an additional 202,867 shares in the last quarter. Principal Financial Group Inc. increased its position in TransMedics Group by 260.1% in the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after purchasing an additional 146,115 shares during the last quarter. Hood River Capital Management LLC purchased a new stake in shares of TransMedics Group during the 2nd quarter worth about $18,854,000. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of TransMedics Group during the 2nd quarter worth about $16,086,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

TMDX has been the topic of a number of research reports. JPMorgan Chase & Co. dropped their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a report on Tuesday, October 29th. Robert W. Baird reduced their price objective on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. Piper Sandler lowered their target price on shares of TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. TD Cowen cut their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Finally, Canaccord Genuity Group decreased their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus target price of $131.80.

TransMedics Group Price Performance

NASDAQ TMDX opened at $86.71 on Monday. The stock has a 50-day simple moving average of $111.69 and a 200 day simple moving average of $136.16. TransMedics Group, Inc. has a twelve month low of $68.84 and a twelve month high of $177.37. The stock has a market capitalization of $2.91 billion, a PE ratio of 92.24 and a beta of 2.08. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.12) earnings per share. Research analysts anticipate that TransMedics Group, Inc. will post 1.01 EPS for the current year.

Insider Activity at TransMedics Group

In related news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. This trade represents a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This trade represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,958 shares of company stock worth $3,470,328 in the last ninety days. 7.00% of the stock is currently owned by insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.